CanCure Revenue and Competitors
Estimated Revenue & Valuation
- CanCure's estimated annual revenue is currently $775k per year.
- CanCure's estimated revenue per employee is $155,000
Employee Data
- CanCure has 5 Employees.
- CanCure grew their employee count by 0% last year.
CanCure's People
| Name | Title | Email/Phone |
|---|
CanCure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is CanCure?
CanCure LLC is an anticancer drug development startup venture with the mission to transform the proprietary innovative cancer immunotherapeutic technology into clinic. CanCure specializes in antibodies that can revitalize patients' own natural immune function to fight cancer. CanCure currently focuses on taking its leading product CuraB-10 into clinic in the very near future. CuraB-10 is a first-in-class monoclonal antibody targeting a tumor-released immune suppressive molecule soluble MIC (sMIC). CuraB-10 monotherapy demonstrated remarkable effectiveness and safety in inducing regression of advanced cancers in small animal models. CuraB10 also remarkably enhances tumor response to immune check point therapies when used in combination.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 5 | 0% | $25.9M |
#2 | $0.1M | 5 | -77% | $6.5M |
#3 | $0.1M | 5 | -29% | $60.2M |
#4 | $0.5M | 5 | N/A | N/A |
#5 | $0.4M | 5 | -29% | N/A |